{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:58:23Z","timestamp":1781780303184,"version":"3.54.5"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2026,4,19]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An updated comprehensive assessment of the burden of hospitalised viral lower respiratory tract disease (LRTD) is especially salient after the COVID-19 pandemic. Therefore, we aimed to comprehensively describe clinical characteristics and outcomes of US adults hospitalised with viral LRTD between 2015 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective analysis, adults hospitalised between 1 January 2015 and 31 March 2023 were identified using Optum\u2019s deidentified Clinformatics Data Mart Database. Index date was the first\n                      <jats:italic>International Classification of Diseases, 9th\/10th Revision<\/jats:italic>\n                      (ICD-9\/10) code for viral LRTD hospitalisation. Outcomes included intensive care unit (ICU) admission, non-invasive ventilation (NIV), invasive mechanical ventilation\/extracorporeal membrane oxygenation (IMV\/ECMO), costs, 30-day mortality and 30-day readmissions. Outcomes were stratified by viral aetiology (\n                      <jats:italic>ICD-9\/10<\/jats:italic>\n                      ), clinical severity and time period (2015\u20132019; 2020\u20132021; 2022\u20132023). Time-to-event data were assessed using Kaplan-Meier estimates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 387\u2009449 patients hospitalised for viral LRTD, 38.1% were admitted to ICU within 30 days of index (84.6% of these were admitted on index date); 8.4% and 8.7%, respectively, received NIV and IMV\/ECMO within 30 days of index and 30-day mortality was 15.1%. Median (IQR) length of stay and mean (SD) hospitalisation costs were 7 (4\u201315) days and $42 752 ($44 841), respectively. Admission to ICU, mortality and costs were substantial across all aetiologies but peaked from 2020 to 2021; readmissions and costs remained high even into 2022\u20132023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Severe viral LRTD incurred substantial burden for US healthcare systems across all viral aetiologies, even in non-pandemic years, with frequent ICU admission and ventilation use, and with considerable associated costs. Readmission rates and costs remain high even after the peak of COVID-19.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003552","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:45:39Z","timestamp":1781779539000},"page":"e003552","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes and costs associated with viral lower respiratory tract disease hospitalisations"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8646-137X","authenticated-orcid":false,"given":"Ekaterina","family":"Maslova","sequence":"first","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca UK Limited, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Fager\u00e5s","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca R&D Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trung","family":"Tran","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca R&D Gaithersburg, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Emmanuel","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca R&D Gaithersburg, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Khezrian","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca UK Limited, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Branscombe","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca UK Limited, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Johnson","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca UK Limited, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Dalal","sequence":"additional","affiliation":[{"name":"ZS Associates India Private Limited, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashmath Ulla","family":"Syed","sequence":"additional","affiliation":[{"name":"ZS Associates India Private Limited, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Yehya","sequence":"additional","affiliation":[{"name":"Pediatric Sepsis Program and Division of Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Children\u2019s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"2026061803451641000_13.1.e003552.1","doi-asserted-by":"crossref","unstructured":"Boncristiani HF , Criado MF , Arruda E . Respiratory viruses. In: Encyclopedia of microbiology. 2009: 500\u201318.","DOI":"10.1016\/B978-012373944-5.00314-X"},{"key":"2026061803451641000_13.1.e003552.2","doi-asserted-by":"publisher","DOI":"10.1093\/INFDIS\/JIY662"},{"key":"2026061803451641000_13.1.e003552.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00510-2"},{"key":"2026061803451641000_13.1.e003552.4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40121-023-00904-z","article-title":"Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile","volume":"13","author":"Weycker","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026061803451641000_13.1.e003552.5","doi-asserted-by":"crossref","first-page":"101000","DOI":"10.1016\/j.mam.2021.101000","article-title":"Interplay between hypoxia and inflammation contributes to the progression and severity of respiratory viral diseases","volume":"81","author":"Bhattacharya","year":"2021","journal-title":"Mol Aspects Med"},{"key":"2026061803451641000_13.1.e003552.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800385"},{"key":"2026061803451641000_13.1.e003552.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00158-0"},{"key":"2026061803451641000_13.1.e003552.8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-021-03914-4","article-title":"Burden and characteristics of COVID-19 in the United States during 2020","volume":"598","author":"Pei","year":"2021","journal-title":"Nature"},{"key":"2026061803451641000_13.1.e003552.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.08.008"},{"key":"2026061803451641000_13.1.e003552.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00138-7"},{"key":"2026061803451641000_13.1.e003552.11","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.ajt.2023.10.010","article-title":"Characteristics and Outcomes Among Adults Aged \u226560 Years Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus \u2014 RSV-NET, 12 States, July 2022\u2013June 2023","volume":"23","author":"Havers","year":"2023","journal-title":"Am J Transplant"},{"key":"2026061803451641000_13.1.e003552.12","unstructured":"Demographic trends of COVID-19 deaths in the US reported to NVSS. CDC COVID data tracker: total deaths by race\/ethnicity, age, and sex; Atlanta, GA Centers for Disease Control and Prevention; 2024. Available: https:\/\/covid.cdc.gov\/covid-data-tracker\/#demographics"},{"key":"2026061803451641000_13.1.e003552.13","unstructured":"Disease burden of flu. Atlanta, GA Centers for Disease Control and Prevention; 2024. Available: https:\/\/www.cdc.gov\/flu\/about\/burden\/index.html"},{"key":"2026061803451641000_13.1.e003552.14","unstructured":"RSV in older adults and adults with chronic medical conditions. Atlanta, GA Centers for Disease Control and Prevention; 2024. Available: https:\/\/www.cdc.gov\/rsv\/high-risk\/older-adults.html"},{"key":"2026061803451641000_13.1.e003552.15","first-page":"195","article-title":"The effects of the COVID-19 pandemic on community respiratory virus activity","volume":"21","author":"Chow","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2026061803451641000_13.1.e003552.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47757-9","article-title":"Deviations in RSV epidemiological patterns and population structures in the United States following the COVID-19 pandemic","volume":"15","author":"Rios-Guzman","year":"2024","journal-title":"Nat Commun"},{"key":"2026061803451641000_13.1.e003552.17","unstructured":"Monitoring COVID-19, respiratory syncytial virus (RSV), and influenza. respiratory virus hospitalization surveillance network (RESP-NET). Atlanta, GA Centers for Disease Control and Prevention; 2024. Available: https:\/\/www.cdc.gov\/resp-net\/dashboard\/index.html"},{"key":"2026061803451641000_13.1.e003552.18","unstructured":"Kelen GD , Wolfe R , D\u2019Onofrio G , et al . Emergency department crowding: the canary in the health care system, 2. Catalyst Non-Issue Content, 2021."},{"key":"2026061803451641000_13.1.e003552.19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.33964","article-title":"Hospital Occupancy and Emergency Department Boarding During the COVID-19 Pandemic","volume":"5","author":"Janke","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026061803451641000_13.1.e003552.20","doi-asserted-by":"crossref","DOI":"10.1002\/emp2.13036","article-title":"Impact of emergency department-based intensive care unit on outcomes of decompensating boarding emergency department patients","volume":"4","author":"Doan","year":"2023","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"2026061803451641000_13.1.e003552.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2020.113443"},{"key":"2026061803451641000_13.1.e003552.22","unstructured":"National healthcare quality and disparities report. Rockville (MD), 2021."},{"key":"2026061803451641000_13.1.e003552.23","doi-asserted-by":"publisher","DOI":"10.7326\/m20-6306"},{"key":"2026061803451641000_13.1.e003552.24","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10070809","article-title":"Coinfections with Bacteria, Fungi, and Respiratory Viruses in Patients with SARS-CoV-2: A Systematic Review and Meta-Analysis","volume":"10","author":"Alhumaid","year":"2021","journal-title":"Pathogens"},{"key":"2026061803451641000_13.1.e003552.25","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13110993","article-title":"Burden and Risk Factors for Coinfections in Patients with a Viral Respiratory Tract Infection","volume":"13","author":"Santus","year":"2024","journal-title":"Pathogens"},{"key":"2026061803451641000_13.1.e003552.26","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12994"},{"key":"2026061803451641000_13.1.e003552.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100802","article-title":"Excess mortality in England post COVID-19 pandemic: implications for secondary prevention","volume":"36","author":"Pearson-Stuttard","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026061803451641000_13.1.e003552.28","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics . National vital statistics system, mortality 2018-2022 on CDC WONDER online database, released in 2024. n.d. Available: http:\/\/wonder.cdc.gov\/ucd-icd10-expanded.html"},{"key":"2026061803451641000_13.1.e003552.29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.xjon.2020.02.003","article-title":"Contemporary analysis of charges and mortality in the use of extracorporeal membrane oxygenation: A cautionary tale","volume":"1","author":"Hayanga","year":"2020","journal-title":"JTCVS Open"},{"key":"2026061803451641000_13.1.e003552.30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chest.2024.01.022","article-title":"Costs of End-of-Life Hospitalizations in the United States for People With Pulmonary Diseases","volume":"166","author":"Lehr","year":"2024","journal-title":"Chest"},{"key":"2026061803451641000_13.1.e003552.31","doi-asserted-by":"crossref","first-page":"936","DOI":"10.18553\/jmcp.2022.22050","article-title":"Direct health care costs associated with COVID-19 in the United States","volume":"28","author":"DeMartino","year":"2022","journal-title":"JMCP"},{"key":"2026061803451641000_13.1.e003552.32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/13696998.2024.2309835","article-title":"Economic burden of COVID-19 for employers and employees in the United States","volume":"27","author":"Sell","year":"2024","journal-title":"J Med Econ"},{"key":"2026061803451641000_13.1.e003552.33","unstructured":"Bell D , Gaal M , Houchens P , et al . 2023 Milliman Medical Index. Milliman Research Report. 2023 Available: https:\/\/us.milliman.com\/en\/insight\/2023-milliman-medical-index#1"},{"key":"2026061803451641000_13.1.e003552.34","unstructured":"European Centre for Disease Prevention and Control . Acute respiratory infections in the EU\/EEA: epidemiological update and current public health recommendations. 2023. Available: https:\/\/www.ecdc.europa.eu\/en\/news-events\/acute-respiratory-infections-eueea-epidemiological-update-and-current-public-health"},{"key":"2026061803451641000_13.1.e003552.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00176-2"},{"key":"2026061803451641000_13.1.e003552.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107958"},{"key":"2026061803451641000_13.1.e003552.37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.50832","article-title":"Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease","volume":"7","author":"Tartof","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:45:51Z","timestamp":1781779551000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,18]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjresp-2025-003552"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003552","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}